Filing Analysis
SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to Dr. Michael J. Haller at the University of Florida to support the PRISE-hATG clinical study. This study evaluates SAB-142 in patients with Stage 3 Type 1 Diabetes (T1D).
📋 Key Facts
- Grant awarded by Breakthrough T1D, a leading global T1D research and advocacy organization.
- The grant supports the PRISE-hATG clinical study.
- Study focus: Evaluating SAB-142 in patients with Stage 3 T1D (those requiring insulin).
- Principal Investigator: Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida.
SAB Biotherapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Shareholders elected four Class II directors and ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 18, 2026.
- Quorum achieved with 59,349,534 shares present (approx. 76.12% of the 77,966,409 shares entitled to vote).
- Elected Class II directors: Dr. David Zaccardelli, Katie Ellias, David Link, and Andrew Moin.
- Ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 59,319,363 votes in favor.
SAB Biotherapeutics entered into a Master Manufacturing Services Agreement with Emergent BioSolutions for the clinical and commercial manufacturing of its product candidate, SAB-142. The agreement includes a five-year term post-FDA approval and a significant $36 million minimum spend commitment.
🚩 Red Flags
- High financial commitment of $36 million relative to typical micro-cap liquidity.
- Exclusive manufacturing rights granted to Emergent, creating a single-source dependency.
- Significant termination penalties requiring payment of remaining contract value upon default or insolvency.
📋 Key Facts
- Agreement signed on April 28, 2026, with Emergent BioSolutions Canada Inc.
- The contract covers manufacturing for SAB-142 at Emergent's Canadian facility.
- Term lasts for 5 years starting from the date of FDA approval.
- Minimum aggregate spend of $36 million is required following FDA approval.
- Emergent is granted sole and exclusive rights to manufacture the product during the term.
- Termination by Emergent for company default requires payment of the minimum annual spend for all remaining years.
SAB Biotherapeutics released a corporate presentation and press release providing clinical data from its Phase 1 HUMAN trial of SAB-142, a human anti-thymocyte biologic targeting Type 1 Diabetes.
📋 Key Facts
- Announced Phase 1 data for SAB-142 in the HUMAN clinical trial on April 22, 2026.
- Furnished a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) detailing the data.
- The trial focuses on a human anti-thymocyte biologic for Type 1 Diabetes (T1D) and other discovery programs.
SAB Biotherapeutics entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to generate approximately $69.7 million in net proceeds. The offering involves over 19 million shares priced at $3.85 per share and includes a 30-day underwriter option for additional shares.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of over 22 million combined shares and warrant-equivalent shares
📋 Key Facts
- Offering of 19,324,677 shares of common stock at $3.85 per share
- Issuance of 2,753,246 pre-funded warrants at $3.8499 each with a $0.0001 exercise price
- Underwriters include Jefferies LLC, UBS Securities LLC, Citigroup Global Markets Inc., and Barclays Capital Inc.
- Estimated net proceeds of $69.7 million, potentially increasing to $81.7 million if the over-allotment option is fully exercised
- The offering is conducted under an existing shelf registration statement on Form S-3 (File No. 333-292482)
SAB Biotherapeutics announced positive Phase 1 clinical data for its SAB-142 candidate in adult patients with established Type 1 Diabetes (T1D). The data demonstrated early signals of C-peptide preservation at Day 120, suggesting the drug may help maintain beta cell function.
🚩 Red Flags
- Extremely small sample size (n=4 for the treatment group) limits the statistical significance of the findings.
- One of the two placebo participants discontinued the study early for personal reasons, leaving only one placebo comparator for the Day 120 endpoint.
- The data is short-term (120 days), whereas T1D disease modification typically requires longer-term observation.
📋 Key Facts
- The Phase 1 HUMAN clinical trial evaluated SAB-142 in a cohort of 6 adult participants (4 treated, 2 placebo).
- SAB-142 treated participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline.
- The single placebo participant who completed the study through Day 120 showed a decrease in C-peptide levels.
- Treated participants received a dose of 2.5 mg/kg of SAB-142.
- The study participants were aged 19 to 40 years with Stage 3 T1D diagnosis within 28-40 months of randomization.
SAB Biotherapeutics, Inc. filed an 8-K to provide notice of an updated corporate presentation posted on its official website.
📋 Key Facts
- The filing is a disclosure under Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was released on January 12, 2026.
- The information in the presentation is furnished but not 'filed' for purposes of the Exchange Act.
SAB Biotherapeutics, Inc. announced the appointment of David Zaccardelli, Pharm.D., and Rita Jain, M.D., to its Board of Directors, effective January 5, 2026. Dr. Zaccardelli will assume the role of Chairperson of the Board.
🚩 Red Flags
- Board appointments are tied to a specific investor (RA Capital Healthcare Fund, L.P.) via a prior private placement agreement, indicating significant investor influence over governance.
📋 Key Facts
- David Zaccardelli appointed as Class II Director and Chairperson of the Board on Jan 5, 2026.
- Rita Jain appointed as Class II Director on Jan 5, 2026.
- Both appointments follow a recommendation from RA Capital Healthcare Fund, L.P. per a July 21, 2025 letter agreement.
- Dr. Zaccardelli has an extensive background including CEO roles at Verona Pharma plc and Dova Pharmaceuticals.
- Dr. Jain brings significant clinical leadership experience from companies like Avalo Therapeutics, AnaptysBio, and Celldex Therapeutics.
SAB Biotherapeutics has entered into a new $75 million 'At the Market' (ATM) offering program with UBS Securities LLC to fund pipeline development and working capital. This replaces a previously terminated $20 million ATM program with Cantor Fitzgerald.
🚩 Red Flags
- Increased dilution potential: The new offering capacity ($75M) is significantly larger than the previously terminated program ($20M).
- Continuous need for capital: The intent to use proceeds for 'working capital' often indicates a high burn rate common in biotech micro-caps.
📋 Key Facts
- Entered into a Sales Agreement with UBS Securities LLC on December 29, 2025.
- The new ATM program allows for the sale of common stock up to an aggregate price of $75,000,000.
- Proceeds are intended for pipeline development and general corporate/working capital purposes.
- UBS will receive a commission of up to 3% of gross proceeds on each sale.
- The company terminated its previous $20 million ATM program with Cantor Fitzgerald effective December 17, 2025.
SAB Biotherapeutics, Inc. announced the resignation of two Board members, Christine Hamilton and Jeffrey Spragens, effective September 30, 2025. The resignations result in a reduction of the Board size from 11 to nine members.
🚩 Red Flags
- Board size reduction following a private placement agreement with an institutional investor (RA Capital) suggests potential shifts in governance control or restructuring of board seats as part of financing terms.
📋 Key Facts
- Christine Hamilton resigned from the Board of Directors on September 30, 2025.
- Jeffrey Spragens resigned from the Board of Directors on September 30, 2025.
- The Board size decreased from 11 members to 9 members.
- Resignations were made in accordance with a letter agreement dated July 21, 2025, with RA Capital Healthcare Fund, L.P.
- The company stated the resignations were not due to any disagreement regarding operations, policies, or practices.
SAB Biotherapeutics, Inc. held a special meeting where stockholders approved two significant proposals: an amendment to the 2021 Omnibus Equity Incentive Plan and a waiver allowing for the conversion of Series B Preferred Stock that could exceed 19.99% of outstanding common stock.
🚩 Red Flags
- Significant potential dilution: The increase in equity incentive plans and the Series B conversion waiver suggest substantial future share issuance.
- Potential Change of Control: The approval of the Series B Nasdaq Conversion Proposal could trigger a change of control under Nasdaq rules, which often impacts existing shareholder voting rights and structure.
📋 Key Facts
- Stockholders approved increasing the maximum shares available under the 2021 Omnibus Equity Incentive Plan by 24,180,000 to a total of 31,932,466 shares.
- Stockholders approved increasing the annual 'evergreen' increase limit from 10,000,000 to 73,750,000 shares.
- Stockholders approved the potential issuance in excess of 19.99% of outstanding Common Stock via conversion of Series B Convertible Preferred Stock (Nasdaq Rule 5635(d) waiver).
- The approval of the Series B conversion may be deemed a 'change of control' under Nasdaq Listing Rule 5635.
- Quorum was met with 54.5% of outstanding shares represented at the meeting.
SAB Biotherapeutics entered into a massive $175 million private placement of Series B Convertible Preferred Stock and warrants to fund its Phase 2b SAFEGUARD study. The deal includes significant dilution potential through conversion rights and warrant exercises, as well as board seat concessions to a major investor.
🚩 Red Flags
- Extreme dilution potential: The convertible preferred stock could result in 100 million new common shares, significantly increasing the float.
- Warrant overhang: Aggregate exercise price of $284 million represents massive future equity issuance.
- Board control shift: Major investor (RA Capital) is gaining two board seats and reducing total board size to nine via a support agreement.
- Restrictive covenants: Series B holders have veto rights over material business changes, liquidation, and IP licensing.
📋 Key Facts
- Entered into a Securities Purchase Agreement on July 21, 2025, for approximately $175 million in gross proceeds.
- Issuance of 1,000,000 shares of Series B Convertible Preferred Stock convertible into up to 100,000,000 shares of common stock at $1.75 per share.
- Issuance of warrants for up to 1,500,000 total shares of Preferred Stock (Release Date and Enrollment Date Warrants).
- Total aggregate exercise price of all warrants is approximately $284 million.
- RA Capital Healthcare Fund, L.P. will nominate two individuals to the Board of Directors via a Letter Agreement.
- The offering requires stockholder approval at a special meeting before conversion can occur.
SAB Biotherapeutics, Inc. held its 2025 Annual Meeting of Stockholders on July 17, 2025. Shareholders approved the election of four Class I directors and ratified the appointment of EisnerAmper LLP as the company's independent auditor for the 2025 fiscal year.
📋 Key Facts
- Annual Meeting held on July 17, 2025.
- Quorum was established with 6,633,125 shares present (approx. 71.38% of outstanding shares).
- Four Class I directors elected: Dr. William Polvino, MD, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler, MD.
- EisnerAmper LLP ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
SAB Biotherapeutics entered into a five-year lease agreement with Sanford Health for laboratory/office space in Sioux Falls, South Dakota. The agreement is effective February 1, 2025.
🚩 Red Flags
- Fixed long-term lease obligation of ~$601k annually for a micro-cap company.
📋 Key Facts
- Entered into 'Sanford Lease Agreement' with Sanford Health on January 30, 2025.
- Lease area: 21,014 square feet located in Sioux Falls, SD.
- Annual rent: $601,630.82.
- Monthly rent: $50,135.90.
- Term: Five years, ending December 31, 2029.
SAB Biotherapeutics announced topline Phase 1 clinical results for its lead candidate, SAB-142, intended to delay the onset or progression of type 1 diabetes. The company scheduled a live webinar and presentation to discuss these results on January 28, 2025.
📋 Key Facts
- Announced topline Phase 1 clinical results for SAB-142 (hIgG) on January 28, 2025.
- SAB-142 is designed to delay the onset or progression of type 1 diabetes.
- The company held a live webinar and presentation to discuss trial results.
SAB Biotherapeutics announced that its Chief Medical Officer will present clinical trial updates for SAB-142 at the EASD 60th Annual Meeting. The filing is a Regulation FD disclosure regarding upcoming scientific presentations.
📋 Key Facts
- Company's CMO to provide an update at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting.
- The presentation focuses on Phase 1 clinical trial data for SAB-142.
- Trial endpoints include safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity.
SAB Biotherapeutics, Inc. announced the appointment of Lucy To as Chief Financial Officer, effective August 12, 2024. Ms. To is a seasoned finance professional with extensive investment banking experience at Wells Fargo and Deutsche Bank.
📋 Key Facts
- Lucy To appointed CFO; start date set for August 12, 2024.
- Ms. To's compensation includes an annual base salary of $475,000 and a potential cash bonus of up to 45% of base salary.
- One-time deferred signing bonus of $125,000 (subject to conditions).
- Equity incentive: 125,000 stock options with a four-year vesting schedule (25% at year one, then monthly over 36 months).
- Mark Conley will return to his previous role as VP of Finance following the transition.
- Ms. To brings significant healthcare investment banking experience from Wells Fargo and Deutsche Bank.
SAB Biotherapeutics, Inc. held its 2024 Annual Meeting of Stockholders on June 27, 2024. Shareholders approved the election of three Class III directors, an amendment to the 2021 Omnibus Equity Incentive Plan, and the ratification of EisnerAmper LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 27, 2024, with a quorum of approximately 73.40% (6,806,137 shares).
- Electing Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.
- Approved amendment to the 2021 Omnibus Equity Incentive Plan to increase available shares by 3,900,000 (totaling 5,500,000).
- Ratified EisnerAmper LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
SAB Biotherapeutics announced a leadership transition in its finance department, featuring the resignation of CFO Michael King, Jr. and the appointment of Mark Conley as Interim CFO, effective June 4, 2024.
🚩 Red Flags
- Sudden departure of a CFO can sometimes precede financial scrutiny, though the filing explicitly states no disagreement exists.
- The appointment is for an 'Interim' role, suggesting the company has not yet secured a permanent successor.
📋 Key Facts
- Michael King, Jr. resigned as CFO on May 26, 2024, to pursue another opportunity; he stated there was no disagreement with the company regarding operations or policies.
- Mark Conley appointed as Interim CFO effective June 4, 2024.
- Conley's compensation includes a $303,000 annual base salary and options for 250,000 shares (subject to post-split adjustments).
- Conley previously served as VP of Finance at the company since November 2023.
SAB Biotherapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for SAB-142, a therapy targeting type 1 diabetes. This allows the company to proceed with clinical development of this specific asset.
📋 Key Facts
- FDA clearance received for Investigational New Drug (IND) application regarding SAB-142.
- SAB-142 is being developed as a therapy for type 1 diabetes.
- The announcement was made via press release on May 21, 2024.
SAB Biotherapeutics, Inc. announced the appointment of Dr. Jay S. Skyler to its Board of Directors as a Class I director, effective May 3, 2024.
📋 Key Facts
- Dr. Jay S. Skyler appointed as Class I director on May 3, 2024.
- Term lasts until the 2025 annual meeting of stockholders or successor election.
- Dr. Skyler has extensive experience including board roles at DexCom, Inc., Amylin Pharmaceuticals, and MiniMed, Inc.
- Compensation is consistent with other non-employee directors as disclosed in the FY2023 Form 10-K.
SAB Biotherapeutics announced the completion of dosing for cohort 3 in its Phase 1 trials of SAB-142. The company reported no instances of serum sickness observed during this phase.
📋 Key Facts
- Completed dosing of cohort 3 for Phase 1 trials of SAB-142.
- Reported zero instances of serum sickness in the trial cohort.
- Company scheduled a corporate update press release on or about April 16, 2024.
SAB Biotherapeutics, Inc. filed an 8-K to furnish its financial results for the fiscal year and quarter ended December 31, 2023, along with a corporate update via press release.
📋 Key Facts
- Report covers financial results for the year and quarter ended December 31, 2023.
- The filing includes a corporate update issued on March 29, 2024.
- Financial statements are provided in Exhibit 99.1.
SAB Biotherapeutics announced new executive employment agreements for its President, Eddie J. Sullivan, PhD, and Chief Operating Officer, Christoph Bausch, PhD, MBA, both effective retroactively to January 1, 2024.
🚩 Red Flags
- Retroactive effective dates (January 1, 2024) for executive compensation changes announced in March may indicate a mid-year restructuring of management incentives or compensation packages.
📋 Key Facts
- Eddie J. Sullivan (President) entered a new agreement with an annual base salary of $485,000 and potential bonus up to 50%.
- Christoph Bausch (COO) entered a new agreement with an annual base salary of $425,000 and potential bonus up to 40%.
- Both agreements replace prior employment agreements in their entirety.
- The effective date for both new agreements is January 1, 2024.
SAB Biotherapeutics, Inc. announced a leadership transition where Samuel J. Reich has been appointed Chief Executive Officer, effective January 30, 2024. He succeeds the previous CEO role (implied by his move from Executive Chairman to CEO), while Eddie J. Sullivan will continue as President overseeing R&D and operations.
📋 Key Facts
- Samuel J. Reich appointed Chief Executive Officer effective January 30, 2024.
- Reich transitions from Executive Chairman of the Board to CEO.
- Eddie J. Sullivan remains President and a member of the Board.
- Sullivan will maintain leadership over operational, research, and development functions.
SAB Biotherapeutics entered into a Controlled Equity Offering℠ Sales Agreement with Cantor Fitzgerald & Co. to facilitate the sale of up to $20,000,000 in common stock via an 'at-the-market' (ATM) offering.
🚩 Red Flags
- Potential for significant shareholder dilution through the ATM offering mechanism.
📋 Key Facts
- Agreement date: January 26, 2024
- Agent: Cantor Fitzgerald & Co.
- Maximum aggregate offering size: $20,000,000
- Offering type: At-the-market (ATM) offering of common stock via Nasdaq
- Agent compensation: 3.0% of aggregate gross proceeds per sale
- Use of proceeds: Pipeline development and general corporate/working capital purposes
SAB Biotherapeutics, Inc. announced that Nasdaq has determined the company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This resolves a previous delisting threat related to share price non-compliance.
🚩 Red Flags
- The filing implies a recent history of being in non-compliance with minimum bid price requirements, which often suggests high volatility or significant downward pressure on the stock price.
📋 Key Facts
- Notification received from Nasdaq on January 23, 2024.
- Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- Nasdaq indicated that the delisting matter is now closed.
SAB Biotherapeutics, Inc. has furnished an updated corporate presentation via Item 7.01 of Form 8-K. The filing does not contain material financial changes or structural shifts, but rather provides summary information for investors.
🚩 Red Flags
- No immediate red flags identified in this specific filing; however, the mention of 'timely funding' and 'cash runway' in the cautionary note suggests ongoing capital requirements typical for micro-cap biotech firms.
📋 Key Facts
- Company provided an updated corporate presentation (Exhibit 99.1) on its website.
- The filing is made pursuant to Item 7.01 of Form 8-K (Regulation FD Disclosure).
- The presentation includes forward-looking statements regarding the T1D program, discovery programs, and private placement tranches.
SAB Biotherapeutics, Inc. announced the approval of a 1-for-10 reverse stock split following a special meeting of stockholders on January 2, 2024. The split is scheduled to become effective at 12:01 a.m. ET on January 5, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance or signal distress).
- Significant reduction in share count which can lead to increased volatility and dilution concerns for existing holders.
📋 Key Facts
- Reverse stock split ratio: 1-for-10 shares.
- Effective date: January 5, 2024, at 12:01 a.m. ET.
- Expected reduction in outstanding common stock from ~92.25 million to ~9.225 million shares.
- The split includes proportionate adjustments to the exercise price of warrants and conversion prices for Series A Preferred Stock.
- Fractional shares will be settled via cash payments based on the January 4, 2024, closing price.